GLP-1 receptor agonists like semaglutide and tirzepatide are linked to significantly lower risks of dementia, ischemic stroke, and all-cause mortality in adults with type 2 diabetes and obesity, according to a large US cohort study
Another disease group that might benefit from treatment with incretin-based therapies is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)
Bioorganic & Medicinal Chemistry, 26(10), 2700-2707
Verified review - view original 10lbs down so far Verified review - view original Great quality medicine, this really works
Research from the STEP trials, which studied semaglutide 2.4mg weekly, found that approximately 75% of the weight lost was fat mass rather than lean mass
Very rarely, eyelid spasms are caused by a more serious brain or nerve disorder